Preeclampsia: state of art and future perspectives. A special focus on possible preventions

Preeclampsia (PE) is characterised by the new onset of hypertension after the 20th week of pregnancy, with or without proteinuria or hypertension that leads to end-organ dysfunction. Since the only definitive treatment is delivery, PE still represents one of the leading causes of preterm birth and p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of obstetrics and gynaecology 2022-07, Vol.42 (5), p.766-777
Main Authors: Kahramanoglu, Özge, Schiattarella, Antonio, Demirci, Oya, Sisti, Giovanni, Ammaturo, Franco Pietro, Trotta, Carlo, Ferrari, Federico, Rapisarda, Agnese Maria Chiara
Format: Article
Language:English
Subjects:
Clinical outcomes
diagnosis
Hypertension
management
Medical diagnosis
outcomes
Preeclampsia
Pregnancy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preeclampsia (PE) is characterised by the new onset of hypertension after the 20th week of pregnancy, with or without proteinuria or hypertension that leads to end-organ dysfunction. Since the only definitive treatment is delivery, PE still represents one of the leading causes of preterm birth and perinatal mobility and mortality. Therefore, any strategies that aim to reduce adverse outcomes are based on early primary prevention, prenatal surveillance and prophylactic interventions. In the last decade, intense research has been focussed on the study of predictive models in order to identify women at higher risk accurately. To date, the most effective screening model is based on the combination of anamnestic, demographic, biophysical and maternal biochemical factors. In this review, we provide a detailed discussion about the current and future perspectives in the field of PE. We will examine pathogenesis, risk factors and clinical features. Moreover, recent developments in screening and prevention strategies, novel therapies and healthcare management strategies will be discussed.
ISSN:0144-3615
1364-6893
DOI:10.1080/01443615.2022.2048810